CLOV vs WKHS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 17, 2026

CLOV

39.0
AI Score
VS
WKHS Wins

WKHS

46.8
AI Score

Investment Advisor Scores

CLOV

39score
Recommendation
SELL

WKHS

47score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CLOV WKHS Winner
Revenue 1.49B 7.89M CLOV
Net Income 55.34M -40.05M CLOV
Net Margin 3.7% -507.6% CLOV
Operating Income 55.34M -40.52M CLOV
ROE 14.7% -558.0% CLOV
ROA 7.7% -36.4% CLOV
Total Assets 720.33M 110.14M CLOV
Current Ratio 1.50 1.28 CLOV
Free Cash Flow 131.55M -40.86M CLOV

Relative Price Performance (Last 90 Days)

CLOV 1M: +6.8% · 3M: -7.7% WKHS 1M: -8.5% · 3M: +8.6%

Current Technical Phase

CLOV

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 53

RSI (14): 53.1 · Price: $4.56

WKHS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 46.7 · Price: $3.03

Fundamentals Snapshot

Metric CLOV WKHS
Market Cap
Forward P/E 28.8 -1.6
Trailing P/E
Revenue (TTM)
Revenue Growth 0.6% 3.7%
Gross Margin 0.2% -0.8%
Operating Margin 0.0% -5.5%
EPS -0.05 -7.87
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, WKHS is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.